Grand Brilliance Group Holdings Limited (HKG:8372)
Hong Kong · Delayed Price · Currency is HKD 0.1540
-0.0020 (-1.28%)
Sep 7, 2026, 7:10 PM HKT
HKG:8372 Revenue
In the fiscal year ending March 31, 2026, Grand Brilliance Group Holdings had annual revenue of 100.71M HKD with 6.63% growth. Grand Brilliance Group Holdings had revenue of 48.22M in the half year ending March 31, 2026, with 18.78% growth.
Revenue
100.71M
Revenue Growth
+6.63%
P/S Ratio
1.22
Revenue / Employee
1.97M
Employees
51
Market Cap
123.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 100.71M | 6.27M | 6.63% |
| Mar 31, 2025 | 94.45M | 12.55M | 15.32% |
| Mar 31, 2024 | 81.90M | 5.20M | 6.78% |
| Mar 31, 2023 | 76.70M | 4.72M | 6.56% |
| Mar 31, 2022 | 71.98M | 1.74M | 2.47% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinopharm Group | 660.27B |
| Charmacy Pharmaceutical | 5.40B |
| ETHK Labs | 3.35B |
| Sinco Pharmaceuticals Holdings | 2.22B |
| Sipai Health Technology | 1.83B |
| ClouDr Group | 1.57B |
| 160 Health International | 784.99M |
| Ziyuanyuan Holdings Group | 423.08M |